NDAQ Stock Recent News

CORAL GABLES, Fla.--(BUSINESS WIRE)---- $RTAC #SPAC--Renatus Tactical Acquisition Corp I (Nasdaq: RTACU) (the “Company”) today announced that, commencing on June 9, 2025, holders of the units (the “Units”) sold in the Company's initial public offering may elect to separately trade the Company's Class A ordinary shares (the “Ordinary Shares”) and warrants (the “Warrants”) included in the Units. The Ordinary Shares and Warrants received from the separated Units will trade on the Nasdaq Global Market (“Nasdaq”) u.

MIDLAND, VA / ACCESS Newswire / June 4, 2025 / Smith-Midland Corporation (NASDAQ:SMID) (the "Company"), a provider of innovative, high-quality proprietary and patented precast concrete products and systems, today announced it received a letter from Nasdaq, dated May 29, 2025, indicating that the Company has regained compliance as it relates to its Annual Report on Form 10-K ("10-K") for the year ended December 31, 2024. The Company's 10-K was filed on May 27, 2025.

Nasdaq claws back gains in 2025 on AI-fueled tech strength and easing trade fears. ETFs like QQQ and QQQM ride the wave.

Real-Time Private Company Dataset Offers Critical Pricing and Valuation Insights for Private Companies, Investors, and Advisors Real-Time Private Company Dataset Offers Critical Pricing and Valuation Insights for Private Companies, Investors, and Advisors

Reestablishing United States Dominance in the Critical Mineral Supply Chain FISHERS, IN / ACCESS Newswire / June 4, 2025 / American Resources Corporation (NASDAQ:AREC) ("American Resources"), a leader in the critical mineral supply chain, developing innovative solutions both upstream and downstream of the refining process, and through its holding in ReElement Technologies Corporation ("ReElement" or "RTC"), a leading U.S. innovator in rare earth element (REE) and critical mineral refining, today announced that Mark Jensen, Chairman and Chief Executive Officer, was recently featured in Nasdaq Amplify Issuer Spotlight interview series at the Nasdaq MarketSite. The Nasdaq Issuer Spotlight interview series explores how industry leaders within the small-cap community are evolving and navigating challenges in various industries.

TEANECK, N.J. , June 4, 2025 /PRNewswire/ --  Cognizant  (Nasdaq: CTSH), a leading provider of information technology, consulting, and business process services, today announced a presentation at the following investor conference:  Nasdaq Investor Conference in Partnership with Jefferies Presenter: Jatin Dalal, Chief Financial Officer Date: Wednesday, June 11, 2025  Time: 2:00PM GMT | 9:00 AM EDT   A live audio webcast of the presentation will be available at Cognizant's website: http://investors.cognizant.com   A replay of the webcasts will remain available on the company's website for 90 days.

Company previously granted extension until June 30, 2025 to regain compliance with Nasdaq's Equity Rule requirement Company previously granted extension until June 30, 2025 to regain compliance with Nasdaq's Equity Rule requirement

SAN FRANCISCO, June 03, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to 11 new employees to purchase an aggregate of 322,000 shares of the Company's common stock, effective as of June 2, 2025. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).

WALTHAM, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective June 1, 2025, the company granted non-qualified stock options to purchase 181,300 shares of its common stock to five new employees under Xilio Therapeutics' 2022 Inducement Stock Incentive Plan.

KUALA LUMPUR, MALAYSIA, June 03, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company that develops innovative cancer medicine, today announced that it has received a letter (the “Compliance Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market Inc. (“Nasdaq”) dated June 3, 2025, informing the Company that it has regained compliance with Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”).